Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

The ROX index (Index combining the respiratory rate with oxygenation) is a prognostic factor for acute respiratory distress syndrome

  • Kenta Nishiyama ,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

    kenta-nishiyama@saiseikaikumamoto.jp

    Affiliation Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan

    ⨯
  • Kazuya Ichikado,

    Roles Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing

    Affiliation Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan

    ⨯
  • Keisuke Anan,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

    Affiliation Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan

    ⨯
  • Kazunori Nakamura,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing

    Affiliation Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan

    ⨯
  • Kodai Kawamura,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing

    Affiliation Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan

    ⨯
  • Moritaka Suga,

    Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing

    Affiliation Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan

    ⨯
  • Takuro Sakagami

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing

    Affiliation Department of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

    ⨯

Abstract

Background

There is no existing reliable and practical method for predicting the prognosis of acute respiratory distress syndrome (ARDS).

Objective

We aimed to clarify the association between the ROX index, which is calculated as the ratio of peripheral oxygen saturation divided by the fraction of inspired oxygen to the respiratory rate, and the prognosis of patients with ARDS under ventilator support.

Methods

In this single-center retrospective cohort study from prospectively collected database, eligible patients were categorized into three groups based on ROX tertiles. The primary outcome was the 28-day survival, and the secondary outcome was 28-day liberation from ventilator support. We performed multivariable analysis using the Cox proportional hazards model.

Results

Among 93 eligible patients, 24 (26%) patients died. The patients were divided into three groups according to the ROX index (< 7.4, 7.4–11, ≥ 11), with 13, 7, and 4 patients dying in the groups, respectively. A higher ROX index was associated with lower mortality; adjusted hazard ratios [95% CIs] for increasing tertiles of ROX index: 1[reference], 0.54[0.21–1.41], 0.23[0.074–0.72] (P = 0.011 for trend) and a higher rate of successful 28-day liberation from ventilator support; adjusted hazard ratios [95% CIs] for increasing tertiles of ROX index: 1[reference], 1.41[0.68–2.94], 2.80[1.42–5.52] (P = 0.001 for trend).

Conclusions

The ROX index at 24 h after initiating ventilator support is a predictor of outcomes in patients with ARDS and might inform initiation of more advanced treatments.

Citation: Nishiyama K, Ichikado K, Anan K, Nakamura K, Kawamura K, Suga M, et al. (2023) The ROX index (Index combining the respiratory rate with oxygenation) is a prognostic factor for acute respiratory distress syndrome. PLoS ONE 18(2): e0282241. https://doi.org/10.1371/journal.pone.0282241

Editor: Rano Mal Piryani, Bilawal Medical College, Liaquat University of Medical and Health Sciences, PAKISTAN

Received: December 14, 2021; Accepted: February 10, 2023; Published: February 27, 2023

Copyright: © 2023 Nishiyama et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All available relevant data are in the paper. The complete dataset is not publicly available because it contains patient-level data that cannot be properly de-identified or aggregated. For more information on this dataset, please contact Medical Ethics Committee. Inquiries regarding this dataset should be directed to natsuko-imura@saiseikaikumamoto.jp or kazuya-ichikado@saiseikaikumamoto.jp.

Funding: The authors received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Acute respiratory distress syndrome (ARDS) is a potentially fatal condition induced by various pulmonary or extrapulmonary diseases that can cause non-cardiogenic pulmonary edema. The global burden of ARDS remains high, with approximately three million patients being diagnosed with ARDS annually. ARDS accounts for approximately 10% of intensive care unit admissions. Moreover, 24% of patients under mechanical ventilation in the intensive care unit suffer from ARDS [1, 2]. The severity and prognosis of ARDS should be considered during treatment decision-making.

The severity of ARDS is widely classified using the Berlin definition. This categorization system also includes treatment decisions, such as the initiation of extracorporeal membrane oxygenation, and prognosis assessment [3]. Moreover, it was validated in a patient-level meta-analysis of 4188 patients with ARDS, which found a hospital mortality rate of 27%, 32%, and 45% for mild, moderate, and severe ARDS, respectively [4]. However, there is controversy surrounding the use of the Berlin definition. Specifically, it is limited by inconsistencies in the time of measurement of the arterial oxygen tension (PaO2)/fraction of inspired oxygen (FiO2) ratio after ventilator support initiation [5] and variations in the PaO2/FiO2 ratio based on the positive end-expiratory pressure (PEEP) [6] and tidal volume [7]. Furthermore, the Berlin definition has been considered as unreliable for predicting prognosis [8]. There is a need to develop new measures that consider ventilator settings, including PEEP. Recently, the ratio of peripheral oxygen saturation (SpO2) divided by the FiO2 to the respiratory rate (ROX index) has been determined as a predictor of positive outcomes after high-flow nasal cannula therapy in patients with severe pneumonia [9, 10].

However, the association of the ROX index with prognosis in patients with ARDS under ventilator support remains unclear. We aimed to clarify the association of the ROX index with the prognosis of patients with ARDS under ventilator support. We hypothesized that a low ROX index is associated with poor prognosis.

Materials and methods

This study was performed according to the Strengthening the Reporting of Observational Studies in Epidemiology statement [11] (S1 Table).

Study design and patient selection

This single-center retrospective observational study was conducted following the tenets of the Declaration of Helsinki and was approved by the Institutional Ethics Committee of the hospital (No: 898). The requirement of informed consent was waived given the retrospective study design. We selected patients from the database [12] of Saiseikai Kumamoto Hospital, which serves as an advanced emergency hospital. This database includes patients diagnosed with ARDS based on the American-European Consensus Conference on ARDS [13] from October 2004 to June 2012, and based on the Berlin definition of ARDS [4] from July 2012 to July 2019. All data, including those in the database, were originally collected continuously and prospectively in our previous study [14–17]. From this database, we selected patients who received ventilator support using an endotracheal tube or non-invasive positive pressure ventilation through a mask for ARDS treatment from October 2011 to July 2019. We excluded patients who died within 24 h of initiating ventilator support, as well as those treated with neuromuscular blockers, high-flow nasal cannula therapy, or extracorporeal membrane oxygenation. Moreover, we excluded patients with pre-existing chronic interstitial lung diseases or other interstitial lung diseases, including acute organizing pneumonia, hypersensitivity pneumonitis, and acute eosinophilic pneumonia. Patients who had underlying cardiogenic edema or Human Immunodeficiency Virus were included, unless they had any exclusion criterion.

The ROX index

The ROX index was defined as the ratio of SpO2 divided by FiO2 (%) to the respiratory rate (breaths/min) [9, 10]. From the records, we noted the patients’ respiratory rate 24 h after ventilator support initiation, and the ROX index was calculated at 24 h after ventilator support initiation. For patients without records at 24 h after ventilator support initiation, we noted the respiratory rate within 2 hours of scheduled timing.

Outcomes

The primary outcome was the 28-day mortality, and the secondary outcome was successful 28-day liberation from ventilator support. The patients were followed up until death or the 28th day in the hospital. Survival was indicated as being alive on the 28th day of hospitalization.

Data collection

Demographic variables were recorded at the time of ARDS diagnosis. Within 24 h of admission to the intensive care unit, we calculated the intensive care unit Acute Physiology and Chronic Health Evaluation (APACHE) II score [18], which is the classification system of disease severity calculated using initial values of 12 routine physiologic measurements, age, and previous health status to provide a general measure of severity of disease, and the Sequential Organ Failure Assessment [19] scores, which is a measure of the degree of organ function failure calculated using six domains involving the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. Moreover, the etiology of ARDS, with respect to whether there was direct or indirect lung injury, was recorded [20]. We assessed findings from chest radiography and blood tests performed before treatment. Additionally, the occurrence of organ failure before and during ventilator support was recorded. Age and PaO2/FiO2 ratio at ARDS diagnosis were considered as confounding variables.

Ventilator support

Ventilator strategies included lung-protective ventilation and optimal PEEP with the following ARDS management objectives [21]: to control tidal volume at 6–8 mL/kg of the ideal body weight (not exceeding 10 mL/kg) and to achieve optimal PEEP. The parameters for each device were set by the physician. Multiple respiratory specialists reached a consensus regarding liberation from mechanical ventilation.

Sample size

Since ARDS is a rare condition, we collected as many patients as possible without calculating the sample size.

Statistical analyses

There were no missing data regarding the ROX index and confounders; therefore, we performed a complete case analysis. Continuous and categorical variables are presented as median (range) and number (percentage), respectively. Patients were categorized into three groups based on the ROX tertiles: low (< 7.4), intermediate (7.4–11), and high (≥ 11). Survival curves were described using the Kaplan–Meier method. We performed univariate and multivariate analyses using Cox proportional hazard models to compare the hazard ratios for each group with those of the reference (low ROX) group. In the multivariate analysis, we adjusted for age and the PaO2/FiO2 ratio. Moreover, we performed the log-rank trend test using the median ROX value within each tertile as an ordinal value. Statistical significance was set at p < .05. Statistical analyses were performed using EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [22] and STATA/SE ver. 16.0 (Stata Corp., College Station, TX, USA).

Results

Patient characteristics

Fig 1 presents the patient flowchart. Among 425 eligible patients, 332 patients were excluded for various reasons, with the remaining 93 patients being included in the analysis. Table 1 presents the demographic characteristics and baseline clinical characteristics. Among the included patients, 68 (73%) patients required endotracheal intubation, while 49 (53%) patients were diagnosed with direct lung injury. Sixty-eight patients (73%) had ARDS from infection. Compared with the other groups, the low ROX group showed a lower PaO2/FiO2 ratio for ARDS diagnosis, rate of endotracheal intubation, C-reactive protein levels, and PEEP, as well as a higher age and APACHE II scores on admission. In the low, intermediate, and high ROX groups, 13, 7, and 4 patients died, respectively; moreover, 13, 16, and 25 patients were successfully liberated from ventilator support within 28 days, respectively.

thumbnail
Download:
Fig 1. A flowchart showing patient inclusion, exclusion, and outcomes.

ECMO: extracorporeal membrane oxygenation, ARDS: acute respiratory distress syndrome, NHFC: nasal high-flow cannula.

https://doi.org/10.1371/journal.pone.0282241.g001

thumbnail
Download:
Table 1. Baseline characteristics of the enrolled patients.

https://doi.org/10.1371/journal.pone.0282241.t001

Twenty-eight-day mortality

The Kaplan–Meier curve and log-rank trend test revealed an inverse relationship between the ROX index and mortality (Fig 2). Similarly, univariate and multivariate analyses (Table 2) showed that a higher ROX index was associated with lower mortality (adjusted hazard ratios [95% confidence intervals (CIs)] for increasing tertiles of ROX index: 1 [reference], 0.54 [0.21–1.41], 0.23 [0.074–0.72]; P = 0.011 for trend).

thumbnail
Download:
Fig 2. Kaplan–Meier curve analysis of the 28-day survival stratified by the ROX index.

https://doi.org/10.1371/journal.pone.0282241.g002

thumbnail
Download:
Table 2. Correlation of the ROX index with outcomes.

https://doi.org/10.1371/journal.pone.0282241.t002

Successful liberation from ventilator support by the 28th day

The Kaplan–Meier curve and log-rank trend test revealed that the ROX index was directly associated with the rate of successful liberation from ventilator support by 28 days (Fig 3). Similarly, univariate and multivariate analyses (Table 2) showed that a higher ROX index was associated with a higher rate of successful liberation from ventilator support by the 28th day (adjusted hazard ratios [95% CIs] for increasing tertiles of ROX index: 1 [reference], 1.41 [0.68–2.94], 2.8 [1.42–5.52]; P = 0.001 for trend).

thumbnail
Download:
Fig 3. Kaplan–Meier curve analysis for the 28-day ventilator liberation stratified by the ROX index.

https://doi.org/10.1371/journal.pone.0282241.g003

Discussion

This study investigated the association between the ROX index and ARDS prognosis. To our knowledge, this is the first study to investigate the association of the ROX index in patients with ARDS under ventilator support, except for high-flow nasal cannula therapy, with prognosis. We found that the ROX index was associated with outcomes. Moreover, the ROX index was inversely and directly associated with the 28-day mortality rate and rate of ventilator withdrawal, respectively.

Our findings demonstrate the usefulness of the ROX index in patients with ARDS under ventilator management. A high ROX index has been reported to predict positive outcomes, including successful liberation from high-flow nasal cannula therapy and low intubation rates [9, 10]. However, these previous studies included patients undergoing high-flow nasal cannula therapy, while we included patients with ventilator support. We found that a higher ROX index was associated with better outcomes, including low mortality and ventilator weaning by day 28, which is consistent with previous findings.

The ROX index is a convenient bedside measure for assessing prognosis. ARDS is currently classified based on the Berlin definition; however, there is still controversy regarding this. Specifically, severity measurement is limited by inconsistencies in the timing of the measurement of the PaO2/FiO2 ratio after ventilator support initiation [5] and variations in the PaO2/FiO2 ratio according to PEEP [6] and tidal volume [7]. Moreover, several biomarkers associated with ARDS have been identified [23]. Studies on biomarkers have further elucidated the pathogenesis of ARDS and indicated the involvement of fibrinolysis [24] and acute inflammation [25, 26], as well as various cells such as lung epithelial cells [27, 28] and endothelial cells [29, 30]. However, there is no single biomarker that can be solely used to predict prognosis. Although combining several biomarkers [31] or fibroproliferative changes on high-resolution computed tomography images [12] can be used to predict prognosis, difficulties in bedside measurements of these data limit their clinical utility. We found that ROX is associated with the prognosis of ARDS after adjustment for age and the PaO2/FiO2 ratio at diagnosis; therefore, it could be a novel measure for assessing the prognosis of ARDS.

Our findings demonstrated that a lower ROX index was associated with poor prognosis. Hypoxia, high FiO2, and tachypnea lead to a low ROX index. Moreover, non-invasive ventilation and low PEEP are closely associated with hypoxia and tachypnea, which lead to a low ROX index. This indicates that the ROX index might reflect the severity of respiratory failure, general conditions such as acidemia, and labored breathing. In the low ROX group, there were more elderly people, patients without endotracheal intubation, and patients with low PEEP. Even after adjustment for age and the PaO2/FiO2 ratio, the ROX index was associated with poor outcomes. This suggests that the ROX index might reflect both the respiratory status and the severity of general conditions, as well as insufficient analgesia and sedation.

Clinical implications

The ROX index may be useful as an indicator for considering advanced treatments. A low ROX index was associated with poor outcomes adjusted for age and the PaO2/FiO2 ratio. It could be considered as a measure of the severity of general condition, analgesia deficiency, sedation, PEEP, and pressure support. Therefore, patients with a low ROX index should be considered for more advanced treatments, including intubation, prone position, neuromuscular blockades, and extracorporeal membrane oxygenation. Since the ROX index can be easily calculated at the bedside, it can inform prompt treatment decisions.

Research implication

The appropriate timing and the cut-off value of the ROX index remain unclear. We calculated the ROX index 24 h after ventilator support initiation based on a previous report that risk stratification based on the Berlin definition was improved by assessing the PaO2/FiO2 ratio 24 h after enrollment rather than at baseline [32]. Further studies are required to clarify the timing and cut-off value.

Strengths and limitations

This is the first study to investigate the association of the ROX index with outcomes in patients with ARDS receiving ventilator support. This study has several limitations. First, this was a single-center retrospective study with a small sample size using a prospectively collected dataset. Compared with a typical retrospective design, our study is strengthened by the use of a prospectively enrolled cohort including prospective identification of acute respiratory failure as suspected ARDS. However, it may introduce an unintentional bias in patient selection. It is unclear whether our findings are useful in other settings; therefore, there is a need for multicenter prospective studies. Second, we only included patients with ARDS; therefore, our findings cannot be generalized to all patients with acute respiratory failure.

Conclusions

Our findings demonstrated that the ROX index measured 24 h after ventilator support initiation was a predictor of outcomes in patients with ARDS. The ROX index can be easily assessed at the bedside and may be useful for informing prompt advanced treatments.

Supporting information

S1 Table. STROBE statement—checklist of items that should be included in reports of observational studies.

https://doi.org/10.1371/journal.pone.0282241.s001

(DOCX)

Acknowledgments

The authors would like to thank Editage (www.editage.com) for English language editing. We also thank Drs. Yuko Yasuda, Yoshitomo Eguchi, Yoshihiko Sakata, Naoki Shingu, Junpei Hisanaga, Tatsuya Nitawaki, Miwa Iio, and Yuko Sekido for their helpful advice.

References

  1. 1. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315: 788–800. pmid:26903337
  2. 2. Fan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. JAMA. 2018;319(7):698–710. pmid:29466596
  3. 3. Ratano D, Fan E. Management of severe ARDS: new strategies and ongoing challenges. Respir Care. 2020;65: 577–580. pmid:32213606
  4. 4. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307: 2526–2533. pmid:22797452
  5. 5. Hedenstierna G. Pulmonary perfusion during anesthesia and mechanical ventilation. Minerva Anestesiol. 2005;71: 319–324. pmid:15886595
  6. 6. Ferguson ND, Kacmarek RM, Chiche JD, Singh JM, Hallett DC, Mehta S, et al. Screening of ARDS patients using standardized ventilator settings: influence on enrollment in a clinical trial. Intensive Care Med. 2004;30: 1111–1116. pmid:14991096
  7. 7. Gowda MS, Klocke RA. Variability of indices of hypoxemia in adult respiratory distress syndrome. Crit Care Med. 1997;25: 41–45. pmid:8989174
  8. 8. Phillips CR. The Berlin definition: real change or the emperor’s new clothes? Crit Care. 2013;17: 174. pmid:23905752
  9. 9. Roca O, Messika J, Caralt B, García-de-Acilu M, Sztrymf B, Ricard JD, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: the utility of the ROX index. J Crit Care. 2016;35: 200–205. pmid:27481760
  10. 10. Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernández G, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019;199: 1368–1376. pmid:30576221
  11. 11. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147: 573–577. pmid:17938396
  12. 12. Ichikado K, Muranaka H, Gushima Y, Kotani T, Nader HM, Fujimoto K, et al. Fibroproliferative changes on high-resolution CT in the acute respiratory distress syndrome predict mortality and ventilator dependency: a prospective observational cohort study. BMJ Open. 2012;2: e000545. pmid:22382117
  13. 13. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149: 818–824. pmid:7509706
  14. 14. Kawamura K, Ichikado K, Takaki M, Sakata Y, Yasuda Y, Shingu N, et al. Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis. Springerplus. 2016;5: 1193. pmid:27516931
  15. 15. Takaki M, Ichikado K, Kawamura K, Gushima Y, Suga M. The negative effect of initial high-dose methylprednisolone and tapering regimen for acute respiratory distress syndrome: a retrospective propensity matched cohort study. Crit Care. 2017;21: 135. pmid:28592332
  16. 16. Anan K, Ichikado K, Kawamura K, Johkoh T, Fujimoto K, Suga M. Clinical characteristics and prognosis of drug-associated acute respiratory distress syndrome compared with non-drug-associated acute respiratory distress syndrome: a single-centre retrospective study in Japan. BMJ Open. 2017;7: e015330. pmid:29122783
  17. 17. Kawamura K, Ichikado K, Takaki M, Eguchi Y, Anan K, Suga M. Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center. Int J Antimicrob Agents. 2018;51: 918–924. pmid:29501821
  18. 18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13: 818–829. pmid:3928249
  19. 19. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22: 707–710. pmid:8844239
  20. 20. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342: 1334–1349. pmid:10793167
  21. 21. Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342: 1301–1308. pmid:10793162
  22. 22. Kanda Y. Investigation of the freely available easy-to-use software ’EZR’ for medical statistics. Bone Marrow Transplant. 2013;48: 452–458. pmid:23208313
  23. 23. Ware LB. Prognostic determinants of acute respiratory distress syndrome in adults: impact on clinical trial design. Crit Care Med. 2005;33 Supplement: S217–S222. pmid:15753731
  24. 24. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med. 2007;35: 1821–1828. pmid:17667242
  25. 25. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med. 2005;33: 1–6; discussion 230–232. pmid:15644641
  26. 26. Parsons PE, Matthay MA, Ware LB, Eisner MD, National Heart, Lung, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288: L426–L431. pmid:15516488
  27. 27. Calfee CS, Ware LB, Eisner MD, Parsons PE, Thompson BT, Wickersham N, et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax. 2008;63: 1083–1089. pmid:18566109
  28. 28. Eisner MD, Parsons P, Matthay MA, Ware L, Greene K, Acute Respiratory Distress Syndrome Network. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax. 2003;58: 983–988. pmid:14586055
  29. 29. Ware LB, Eisner MD, Thompson BT, Parsons PE, Matthay MA. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med. 2004;170: 766–772. pmid:15201135
  30. 30. Sweeney RM, McAuley DF. Acute respiratory distress syndrome. Lancet. 2016;388: 2416–2430. pmid:27133972
  31. 31. Calfee CS, Ware LB, Glidden DV, Eisner MD, Parsons PE, Thompson BT, et al. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med. 2011;39: 711–717. pmid:21283009
  32. 32. Costa EL, Amato MB. The new definition for acute lung injury and acute respiratory distress syndrome: is there room for improvement? Curr Opin Crit Care. 2013;19: 16–23. pmid:23235543